2413. Risk factors of ethambutol optic neuropathy among patients with tuberculosis and NTM infection
Session: Poster Abstract Session: Tuberculosis: Epidemiology and Management
Saturday, October 7, 2017
Room: Poster Hall CD
Background: Ethambutol optic neuropathy (EBON) is the significant side effect of taking ethambutol (EB), and the incidence of EBON has been reported to be around 1%. The risk factors of EBON haven’t been appeared completely.

Methods: We conducted a retrospective study to identify the frequency and the risk factors of EBON, in a medical center located in Tokyo, Japan. Patients diagnosed with tuberculosis (TB) or non-tuberculous mycobacteria (NTM) infection, who received EB, and took examination by ophthalmologists during the study period (April 2013 to March 2016), were included. Ophthalmological evaluation was done around the introduction of EB, and after emerging of any visual problems. We did the chart review, and analyzed the data between patients with and without EBON.

Results: Of the 328 patients, 272 (82.9%) were with TB, and others were with NTM infection (8 are combined). The mean age was 56 years, the median duration of EB administration was 65 days, and the median dosage of EB was 13.7 mg/kg. Ten patients (3.0%) developed EBON during the study period. Rate of the elderly (75 years) (50.0% vs 21.7%; 95%CI, 1.02 to 12.96; p=0.034), and renal dysfunction (Ccr<50) (60.0% vs 18.4%; 95%CI, 1.82 to 24.31; p=0.005) was significantly high in EBON patients compared to non-EBON patients. There were no significant differences in the rate of patients with diabetes, hypertension, and hyperlipidemia.

Conclusion: In our study, incidence ratio of developing EBON was higher than previous reports. Age and renal dysfunction was associated with developing of EBON.

Sachi Matsubayashi, MD, Eriko Morino, M.D, Yoshie Tsujimoto, MD, Naoko Nagano, MD, Tamaki Kakuwa, MD, Keita Sakamoto, MD, Satoru Ishii, MD, Manabu Suzuki, MD, Jin Takasaki, MD, Go Naka, MD, Motoyasu Iikura, MD, Shinyu Izumi, MD, Yuichiro Takeda, MD and Haruhito Sugiyama, M.D Ph.D, Respiratory Medicine, National Center for Global Health and Medicine, Tokyo, Japan

Disclosures:

S. Matsubayashi, None

E. Morino, None

Y. Tsujimoto, None

N. Nagano, None

T. Kakuwa, None

K. Sakamoto, None

S. Ishii, None

M. Suzuki, None

J. Takasaki, None

G. Naka, None

M. Iikura, None

S. Izumi, None

Y. Takeda, None

H. Sugiyama, None

Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 4th with the exception of research findings presented at the IDWeek press conferences.